News

Immix Biopharma and its subsidiary Nexcella are currently conducting a phase 1b/2 clinical trial (NCT06097832; NEXICART-2) in the United States aimed at evaluating…

 “So far, the data is quite promising to share that this is very safe... I'm hoping that by the next 6 months, we will have much more mature data, more…

Light chain (AL) amyloidosis is a rare but serious blood disease that develops when aberrant immune plasma cells produce abnormal “light chain” proteins. These…

The BCMA-directed CAR T-cell therapy NXC-201 led to fast-onset responses that proved durable and were characterized by low-grade cytokine release syndrome (CRS) and…

Topline results were announced from a phase 3 trial evaluating birtamimab in patients with amyloid light chain (AL) amyloidosis.Birtamimab is an investigational…

Immunoglobulin light chain (LC) amyloidosis (AL) is one of the most common types of systemic amyloidosis but there is no reliable in vivo model for better…

Panelists discuss how early diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) relies on clinical awareness, recognizing red flag symptoms, and utilizing…

Although SGLT2 inhibitors have become standard in the management of heart failure with preserved and reduced ejection fraction, their use in patients with ATTR…

AbstractWe report a case of dual amyloidosis with Alzheimer's disease and wild-type transthyretin (ATTRwt) amyloidosis. A 76-year-old man with Alzheimer's disease…

Key takeaways:Vutrisiran improved all-cause mortality and recurrent CV independent of disease severity in cardiac amyloidosis.Regardless of cutoffs, vutrisiran also…